Hgh Treatment For Fatty Liver Disease On The Horizon

Bio-Identical HGH Therapy may be a potent option for patients struggling with NAFLD (Non-Alcoholic Fatty Liver Disease) associated with obesity. A small pilot study was conducted by Dr. Takara Stanley and research partners and was published in the medical journal Clinical Endocrinology.

While this research is in its preliminary phases, the potential is real.

Liver Disease is a growing problem in the United States, owing not only to alcohol and addiction but to obesity. NAFLD is one of the most diagnosed forms of Liver Disease. As the condition increases in severity, it progresses into a condition known as NASH (Non-Alcoholic Steatohepatitis).

What Causes Non-Alcoholic Fatty Liver Disease?

NAFLD is inflammation caused by the accumulation of liver fat. While alcoholism can lead to Fatty Liver Disease, NAFLD specifically refers to Fatty Liver Disease not caused by the abuse of alcohol.

This condition causes cirrhosis, the buildup of scar tissue, and, eventually, liver cancer. A growing body of research suggests that NAFLD strongly correlates with diabetes and obesity, leading to metabolic syndrome.

Other symptoms of metabolic syndrome include obesity centered around the midsection, high blood sugar, elevated blood pressure, increased triglycerides, and high cholesterol.

How Can Human Growth Hormone Treatments Help Patients With Liver Complications?

Many studies have shown that HGH Therapy is very effective at increasing the rate of Liver Regeneration. Currently, there are no FDA-Approved Medical Treatments for NAFLD, leaving doctors to recommend exercise, weight loss, and lifestyle changes merely.

While these holistic options benefit patients, it's critical to find effective treatments to improve the lives of these patients and combat NAFLD/NASH. Human Growth Hormone plays a vital role in metabolism and helps free energy from fat cells for use by the body.

Much of the heavy work associated with Growth and Metabolism is associated with IGF-1 and other Growth Factors/Hormones released in the HGH Hormone Cascade. There is some evidence that diminished HGH Production is one of the contributing factors which lead to obesity. For this study, 24 patients were selected for evaluation (11 males/13 females).

18 patients completed the course, and none left due to side effects. All patients were clinically obese, with a minimum 5% hepatic fat fraction (11% average).

Experimental patients received Norditropin HGH Injections, while the control group received no medical intervention. Researchers discovered that patients taking Growth Hormone Therapy experienced a 36% reduction in liver fat, whereas control patients only saw a decrease of 3.6%.

If Liver Fat falls below 5%, Steatosis is considered resolved. 5 of 9 patients in the experimental group surpassed this goal, whereas only a single untreated patient reached the same outcome.

Other Benefits of HGH for Fatty Liver Disease

HGH Patients also experienced lower levels of several liver enzymes associated with liver damage and inflammation. Beyond that, Growth Hormone Injections improved lean muscle mass, body fat, and BMI. IGF-1 Levels rose to healthy levels, did not increase C-reactive protein, and did not impact blood sugar/fat. While future study is necessary, the results are favorable, in line with similar research in human and animal models.

Contact us for a FREE, no-obligation discussion about the benefits of Human Growth Hormone (HGH) Replacement Therapy.

Word Count: 524